Company: MGLD
Filing Date: 2025-01-27
Form Type: 424B5
Source: 0001493152-25-003788
Chunk: 8

Company: Marygold Companies, Inc.
Filing Date: 2025-01-27
Form: 424B5
Chunk 8
---
 a discussion of the factors you should consider carefully before investing 
 in our shares.                                                                                                                           |

Except as otherwise stated herein, all information in this prospectus supplement related to the number of shares of our common stock to be outstanding immediately after this offering is based on 40,187,820 shares of our common stock outstanding as of December 31, 2024. The number of shares outstanding as of December 31, 2024, excludes:

| ● | 640,881                                                                                                                            
 shares of common stock issuable upon exercise of stock options outstanding as of December 31, 2024, at a weighted average exercise 
 price of $1.35 per share;                                                                                                          |
| ● | 3,390,639                                                                                                                          
 shares reserved for future issuance pursuant to our 2021 Omnibus Equity Incentive Plan as of December 31, 2024; and                |
| ● | 987,200                                                                                                                            
 shares issuable upon conversion of outstanding shares of Series B, Voting, Convertible Preferred Stock (“Series B Preferred        
 Stock”).                                                                                                                           |

Unless otherwise indicated, all information in this prospectus supplement reflects or assumes the following:

| ● | no                                                                                                            
 exercise of outstanding stock options, described above;                                                       |
| ● | no                                                                                                            
 conversion of outstanding shares of Series B Preferred Stock; and                                             |
| ● | no                                                                                                            
 exercise by the underwriters of their overallotment option to purchase up to 307,500 shares in this offering. |

| S-8 |

<div align='center'>RISK FACTORS</div>

Investing in our shares involves a high degree of risk and dilution. You should carefully consider the risks, uncertainties and other factors described in our Annual Report on Form 10-K for the year ended June 30, 2024, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we have filed or will filed with the SEC, and in other documents incorporated by reference to our filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act and all other information contained or incorporated by reference in this prospectus supplement and the accompanying base prospectus, including our consolidated financial statements and the related notes, before investing in our common stock. If any of these risks materialize, our business, financial condition or results of operations could be materially harmed. In that case, the trading price of our common stock could decline